Edition:
India

Paion AG (PA8G.DE)

PA8G.DE on Xetra

2.21EUR
20 Jul 2018
Change (% chg)

€-0.01 (-0.67%)
Prev Close
€2.23
Open
€2.29
Day's High
€2.30
Day's Low
€2.19
Volume
25,769
Avg. Vol
48,374
52-wk High
€3.06
52-wk Low
€2.01

Latest Key Developments (Source: Significant Developments)

Paion Raises EUR 5.2 Million In Private Placement
Thursday, 21 Jun 2018 

June 21 (Reuters) - Paion AG ::PAION AG RAISES EUR 5.2 MILLION IN PRIVATE PLACEMENT.WILL USE PROCEEDS TO PREPARE NECESSARY WORK FOR SUBMISSION OF EU MARKET APPROVAL DOSSIER FOR REMIMAZOLAM.ALL SHARES WILL BE PLACED WITH FINANCIÈRE ARBEVEL, FRENCH INSTITUTIONAL INVESTOR, AT PRICE OF EUR 2.00 PER SHARE.CAPITAL INCREASE CONSISTS OF APPROXIMATELY 4% OF PAION'S CURRENT REGISTERED SHARE CAPITAL.REGISTERED SHARE CAPITAL WILL AMOUNT TO EUR 63,720,046.00.  Full Article

PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan
Monday, 18 Dec 2017 

Dec 18 (Reuters) - PAION AG ::SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN.EUR 1 MILLION UPFRONT PAYMENT TO PAION.ADDITIONAL REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO EUR 25 MILLION.ROYALTIES RANGING FROM LOW DOUBLE-DIGITS TO OVER 20%.  Full Article

PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - PAION AG :‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT.‍NO SECOND INTRANASAL STUDY REQUIRED​.‍ASSUMES CLINICAL DEVELOPMENT PROGRAM FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN U.S. AS COMPLETED​.  Full Article

PAION ‍9-mth net loss at 8.5 mln euros
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - PAION AG :DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017.‍CASH POSITION OF EUR 29.6 MILLION AS OF 30 SEPTEMBER 2017​.‍REVENUES IN FIRST NINE MONTHS OF 2017 AMOUNTED TO KEUR 5,097 COMPARED TO KEUR 2,230 IN PRIOR-YEAR PERIOD​.‍RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO KEUR 13,528 IN FIRST NINE MONTHS OF 2017​.‍9MTH NET LOSS AMOUNTED TO KEUR 8,508. IN PRIOR-YEAR PERIOD, A NET LOSS OF KEUR 16,061 WAS REPORTED​.‍CONFIRMS ITS OUTLOOK FOR FY ANNOUNCED ON 09 AUGUST 2017 WITH PUBLICATION OF HALF-YEAR RESULTS FOR 2017​.  Full Article

Paion: Japan patent office grants dosing patent for remimazolam
Friday, 13 Oct 2017 

Oct 13 (Reuters) - PAION AG ::DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN.‍PATENT PROTECTION UNTIL 2033 IN JAPANESE MARKET​.  Full Article

Paion H1 net loss widens to 13.2 million euros
Wednesday, 10 Aug 2016 

Paion AG : In first half of 2016, revenues were 0.2 million euros ($222,980.00) . Expects revenues of approx. 4 million euros in 2016, which is portion of 10 million euros upfront payment received from Cosmo that will be recognized as revenues in 2016 . Expects research and development expenses to be between 24 million euros and 27 million euros depending on progress of development for FY . Net loss was 13.2 million euros for first half-year 2016 compared to a loss of 11.3 million euros for prior-year period .Net loss is expected to be between 21.5 million euros and 24 million euros, a decrease compared to previous year (2015: 28.2 million euros) for FY.  Full Article

BRIEF-Paion FY Net Loss At EUR 12.1 Million

* SAYS CASH AND CASH EQUIVALENTS OF EUR 24.8 MILLION AS OF 31 DECEMBER 2017